(Q57911735)

4

Giancarlo Comi

0 references

Massimo Filippi

9

Massimo Filippi

0 references

Rupert Sandbrink

13

Rupert Sandbrink

0 references

Christoph Pohling

12

Christoph Pohl

0 references

Barry G W Arnason

3

Barry Arnason

0 references

Timon Bogumil

11

Timon Bogumil

0 references

Karola Beckmann

10

Karola Beckmann

0 references

author name string

Christian Lampl

1

0 references

Stefan Nagl

2

0 references

Paul O′Connor

5

0 references

Stuart Cook

6

0 references

Douglas Jeffery

7

0 references

Hans Peter Hartung

https://scigraph.springernature.com/pub.10.1007/s00415-013-6888-0

14

0 references

publication date

17 March 2013

0 references

published in

Journal of Neurology

0 references

volume

260

0 references

issue

7

0 references

page(s)

1838-1845

0 references

exact match

0 references

cites work

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6888-0

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6888-0

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6888-0

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6888-0

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6888-0

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6888-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6888-0

Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6888-0

The Association of Age and Depression Among the Elderly: An Epidemiologic Exploration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6888-0

21 January 2018

Dizziness in the elderly

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6888-0

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020